NEW YORK and HAIKOU, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign. Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.
HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.
China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases. Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.
"This is an exciting time for China Pharma Holdings, Inc. as we
continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved